What are the medical insurance reimbursement conditions for axitinib/axitinib?

Axitinib/Axitinib is a targeted drug used to treat advanced renal cell carcinoma, particularly in patients who have been treated with other therapies, such as sorafenib or sunitinib. It blocks tumor angiogenesis by inhibiting the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor-α (PDGFR-α) and c-kit, thereby inhibiting tumor growth and metastasis.

In China, axitinib has been included in the scope of medical insurance reimbursement, but specific reimbursement conditions and procedures may vary depending on regions and hospitals. Generally speaking, medical insurance reimbursement usually requires patients to meet certain clinical diagnosis standards and treatment plans. On the one hand, patients need to be diagnosed with metastatic renal cell carcinoma and need to provide relevant medical certification documents, including pathology reports, imaging examination results, etc., to prove the nature and stage of the cancer. In addition, before receiving axitinib treatment, patients usually need to have received other standard therapies, such as immunotherapy, targeted therapy, etc., and these treatments are ineffective or intolerable.

When applying for medical insurance reimbursement, patients must also follow local medical insurance policies, fill in the corresponding application form, and provide a detailed list of treatment costs, including drug fees, examination fees, and related medical service fees. Some regions may also require doctors to provide explanations on the rationality of medication, indicating that axitinib is a suitable choice for the patient's condition.

It is worth mentioning that the dosage and course of treatment of axitinib will also affect medical insurance reimbursement. Doctors usually develop individualized treatment plans based on the patient's specific conditions, and regularly monitor adverse reactions and efficacy during medication in order to adjust the dosage or change treatment plans in a timely manner. This not only helps improve efficacy but also reduces unnecessary financial burden.

Reference materials:https://www.webmd.com/drugs/2/drug-159383/axitinib-oral/details